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mortality worldwide, with approximately 1.6 million new
cases and 1.4 million deaths each year.1 Non-small-cell lung
cancer (NSCLC) accounts for nearly 85% of all cases of lung
cancer. Once diagnosed, the 5-year survival rate of NSCLC
patients hardly reaches 15% despite many different treat-
ments including surgery, radiotherapy, and chemotherapy
being widely used.1 However, the therapeutic effect of
chemotherapy is still not satisfactory in patients with
advanced NSCLC and the response rate is only 20e35% with
a median survival of 10e12 months.
Epidermal growth factor receptor (EGFR) is overex-
pressed in many solid tumors including NSCLC, and the
overexpression of EGFR can affect the pathogenesis of
cancer, such as cell proliferation, invasion, and metas-
tasis. Activated EGFR can recruit a number of downstream
signaling molecules such as phosphatidylinositol 3-kinase
(PI3K)-Akt-mammalian target of rapamycin (mTOR) and
Ras-Raf-MAPK-ERK kinase (MEK).2 Thus, EGFR has been the
focus of molecular-targeted therapies. Drugs that inhibit
the tyrosine kinase activity of EGFR, such as the tyrosine
kinase inhibitors (TKIs) gefitinib and erlotinib, have been
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http://dx.doi.org/10.1016/j.jfma.2012.10.017EGFR-TKIs show good anticancer effects in NSCLC
patients, the efficacy of EGFR-TKIs remains limited mainly
because of acquired resistance in clinics.3 Therefore, it is
very important to investigate the underlying mechanisms
to influence the sensitivity of EGFR-TKIs.
Macroautophagy, hereafter referred to as autophagy, is
an evolutionarily conserved catabolic process involving the
degradation of cytoplasmic constituents, and the recycling
of long-lived or aggregated proteins. In many tumor
cells, autophagy can be upregulated during disadvantaged
conditions, such as chemoradiotherapy or in a nutrient-
deficient environment, and promote tumor cell survival,
thus autophagy may be regarded as a potential mechanism
of drug resistance. For example, inhibition of autophagy
can enhance the effects of apoptosis induced by cisplatin in
esophageal cancer cells.4
The PI3K-Akt-mTOR pathway, as one of the downstream
signaling pathway of EGFR, is one of the two main molec-
ular regulation mechanisms of autophagy, which suggests
a potential link between EGFR-targeted therapy and
induction of autophagy. Another TKI named imatinib can
promote cytoprotective autophagy in many cell lines such
as chronic myeloid leukemia stem cells.5 Therefore, we
propose the hypothesis that autophagy may be a potential
factor influencing the acquired resistance of lung cancer
cells to EGFR-TKIs.
Although autophagy can be induced in many different
cancer cell lines including lung cancer cells, the exact role
of autophagy in tumor cell death or survival is still unclear.
Autophagy can be activated to promote cell survival in& Formosan Medical Association. All rights reserved.
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mediated degradation of cellular proteins and organelles,
and can act as a cellular survival mechanism. Thus, it could
serve as a potent oncogenic mechanism to promote tumor
cell survival.
In fact, many studies have indicated that induction of
autophagy can enhance tumor resistance to different
anticancer therapies in different tumor cell lines.
Chemotherapy-induced high mobility group box 1 (HMGB1)
expression in osteosarcoma cells can promote autophagy,
which could inhibit apoptosis and increase drug resistance.6
In esophageal cancer cells, autophagy can promote the
survival of drug-resistant cancer cells following treatment
with chemotherapeutics.7 In addition, inhibition of auto-
phagy can enhance the growth inhibition and apoptotic
effect of cisplatin in lung acquired resistant cells (A549/
DDP).8 Therefore, these results have indicated that auto-
phagy may play an important role in the drug resistance of
tumor cells to anticancer therapeutics.
Furthermore, other studies have proven that autophagy
can protect tumor cells against the effect of EGFR-TKIs. In
lung cancer cells, autophagy can be activated by EGFR-TKIs
through inhibition of the PI3K/Akt/mTOR signaling
pathway, and inhibition of autophagy can augment the
growth inhibitory effect of EGFR-TKIs.9 Other findings also
suggest that inhibition of autophagy can induce a marked
increase in the death-inducing activity of EGFR-TKIs (erlo-
tinib) in glioblastoma cells.10 Thus, combining conventional
chemotherapy with therapeutic strategies that aim to
inhibit autophagy in patients, that is novel targeted therapy
with EGFR-TKIs, and it may represent a promising approach
with higher efficacy for NSCLC patients.
Previous studies have indicated that inhibition of auto-
phagy can enhance the efficacy of EGFR-TKIs in many
different cancer cells including NSCLC cells.9,10 Therefore,
we propose the hypothesis that autophagy may facilitate
the acquired EGFR-TKI resistance of lung cancer cells,
which might be one of the mechanisms for tumor recur-
rence and metastasis.
In recent years, the role of autophagy in the chemo-
radiotherapy resistance of cancer cells has been explored
extensively. Although the function of autophagy in the
EGFR-TKI acquired resistance is still uncertain and more
studies are needed to investigate the possible resistantmechanism, at least it offers us a new alternative strategy
for overcoming acquired resistance to EGFR-TKIs.
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